Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 119.99

-2.9%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	7/14/2006 10:36:59 AM
	of 276

Illumina to Conduct Custom Genotyping for Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Thursday July 13, 6:01 am ET SAN DIEGO--(BUSINESS WIRE)--July 13, 2006--Illumina, Inc. (NASDAQ:ILMN - News) announced today that it has signed a genotyping services agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD). ADVERTISEMENT Under the terms of the agreement, Illumina will develop custom SNP (single nucleotide polymorphism) content for a multi-sample Sentrix® BeadChip. The BeadChip platform enables analysis of 12 samples and up to 60,000 SNPs per sample on a single BeadChip. Illumina expects to genotype thousands of samples provided by J&JPRD using its Infinium(TM) assay, which can provide array-based deployment and genotyping of virtually any SNP on the genome at effectively unlimited multiplex levels while delivering industry-leading data quality. No further details of the agreement were disclosed. For more about Illumina genotyping services or custom genotyping solutions, contact Customer Solutions at +1 858 202.4566 or e-mail info@illumina.com. About Illumina Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology - used in leading genomics centers around the world - provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next